StreetAlpha.app
Home › Stocks › ABOS

Acumen Pharmaceuticals, Inc. (ABOS)

Members
LATEST PRICE

Acumen Pharmaceuticals develops experimental antibody treatments for Alzheimer's disease. ABOS last reported earnings on Mon, Oct 26, 2026.

Prices, price targets and earnings estimates for ABOS are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is ABOS in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Last report
Oct 26
2026 · Before the open (BMO)
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ABOS in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for ABOSThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
CitigroupMaintained
Sep 15Buy
DateFirmActionRatingPrice target
Sep 15CitigroupMaintainedBuy
Loading…

Whale Options Flow

90D

No whale options trades in ABOS in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABOS is in one of them and how their past ABOS trades turned out.

See how it works→ View all auto pilots→
ABOS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ABOS in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Acumen Pharmaceuticals

Acumen Pharmaceuticals is a biopharmaceutical company based in Newton, Massachusetts, that is developing treatments for Alzheimer's disease. Its lead candidate, sabirnetug, is an antibody designed to target soluble amyloid-beta oligomers, which the company believes play a central role in the disease. Sabirnetug is in a Phase 2 trial for people with mild cognitive impairment or mild dementia due to Alzheimer's. The company is also developing a brain-delivery platform with a partner and does not yet have a product on the market.

Headquarters
Newton, MA
Summary based on the company’s 2026 annual report (10-K) ↗